Q4 2025 Vitrolife AB Earnings Call Transcript

Feb 03, 2026 / 09:00AM GMT

Release Date Price: kr151

Transcript

Key Points

Positve

Vitrolife AB (VTRLY) achieved 6% organic growth in local currencies, excluding discontinued business, surpassing internal forecasts.
Strong performance in the Americas, particularly North America, with 9% organic growth in local currencies.
APAC region reported a 10% organic growth in local currencies, outperforming internal expectations.
The company is focusing on strategic investments in sales and marketing, particularly in North America, which are yielding positive results.
Vitrolife AB (VTRLY) is implementing a restructuring program to focus on key tests and markets with stronger growth prospects.

Negative

Currency effects negatively impacted sales by 10% and gross margin by approximately 2.5 percentage points.
EMEA region faced challenges with a 1% decrease in sales in local currencies, excluding discontinued business.
The gross margin decreased from 61.1% in Q4 2024 to 58.6% in Q4 2025, adjusted for restructuring.
Higher operating expenses due to strategic investments in North America and IT, impacting EBITDA margin.
Genetic services in the Middle East are negatively impacting EMEA results due to clinics insourcing activities.

Operator

Welcome to Vitrolife Q4 2025 earnings call. (Operator Instructions)

Now I will hand the conference over to CEO Bronwyn Brophy and Par Ihrskog.

Bronwyn O;connor

Vitrolife AB - President, Chief Executive Officer

' -

Good morning, everyone, and welcome to the Vitrolife Group Q4 report. I'll now move you to the first slide of the presentation. Let me start with the highlights. We delivered 6% organic growth in local currencies, excluding discontinued business, beating our own internal forecasts for the quarter in relation to the top line. Strong growth in Americas, again driven by North America. I should also call out that APAC also performed very well in the quarter with 10% organic growth in local currencies. And the third point that I would like to highlight is that following a strategic review of our genetic services business, we announced a restructuring program in December. This will allow us to focus on the key tests and markets with stronger prospects for possible growth.

I'll now move you on to the next slide, please, and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.